Summit partner Akeso announced positive overall survival results from the Phase III HARMONi-2 trial in NSCLC. Ivonescimab, licensed for Summit's territories as SMT112, showed statistically significant improvement over pembrolizumab for a key endpoint, reinforcing its potential commercial value.